Clinical trial · Observational
Impact of NBI on Patients Undergoing Endoscopic Eradication Therapy
A Multicenter Study Evaluating the Impact of NBI on Patients With Barrett's Esophagus Associated Neoplasia Undergoing Endoscopic Eradication Therapy (EET)
NCT03191604CI-TRIAL-00041435completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study tests the impact of narrow band imaging (NBI) on endoscopists' accurate detection of visible lesions and dysplasia in patients with Barrett's esophagus, as well as the effect of NBI on the choice of primary treatment modality among endoscopists performing endoscopic eradication therapy (EET).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barrett Esophagus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Video intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Endoscopists familiar with EET
- description
- Physicians familiar with conducting endoscopic eradication therapy.
- interventionNames
- Other: Video intervention
Primary outcomes (1)
- measure
- Altered chosen treatment modality due to NBI
- timeFrame
- 1 year
- description
- Percentage of cases in which use of NBI altered decision-making in regards to initial treatment modality for patients undergoing EET.
Secondary outcomes (3)
- measure
- % visable dysplastic lesions detected
- timeFrame
- 1 year
- description
- Percentage of visible dysplastic lesions detected by HD-WLE and NBI across all participants stratified by subgroup of experience
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Endoscopists familiar with EET. Exclusion Criteria: * Endoscopists not familiar with EET or non-endoscopists. * Special populations will not be included in this study.
References
Publications (18)
- BACKGROUNDSpechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014 Aug 28;371(9):836-45. doi: 10.1056/NEJMra1314704. No abstract available. PMID 25162890
- BACKGROUNDHayeck TJ, Kong CY, Spechler SJ, Gazelle GS, Hur C. The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data. Dis Esophagus. 2010 Aug;23(6):451-7. doi: 10.1111/j.1442-2050.2010.01054.x. Epub 2010 Mar 26. PMID 20353441
- BACKGROUNDIreland CJ, Thompson SK, Laws TA, Esterman A. Risk factors for Barrett's esophagus: a scoping review. Cancer Causes Control. 2016 Mar;27(3):301-23. doi: 10.1007/s10552-015-0710-5. Epub 2016 Feb 5. PMID 26847374
- BACKGROUNDShaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51. doi: 10.1038/ajg.2015.322. Epub 2015 Nov 3. PMID 26526079
- BACKGROUNDIncarbone R, Bonavina L, Saino G, Bona D, Peracchia A. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc. 2002 Feb;16(2):263-6. doi: 10.1007/s00464-001-8161-3. Epub 2001 Nov 16. PMID 11967675
- BACKGROUNDFerguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg. 2002 Jan-Feb;6(1):29-35; discussion 36. doi: 10.1016/s1091-255x(01)00052-x. PMID 11986015
- BACKGROUNDFountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Br J Surg. 2004 Aug;91(8):997-1003. doi: 10.1002/bjs.4591. PMID 15286961